Insider Selling: AtriCure (NASDAQ:ATRC) Insider Sells $201,135.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 3,657 shares of AtriCure stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00. Following the transaction, the insider owned 147,264 shares in the company, valued at approximately $8,099,520. This trade represents a 2.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The stock was sold at an average price of $52.50, for a total value of $407,557.50.

AtriCure Stock Up 3.0%

Shares of ATRC opened at $54.54 on Friday. The business’s 50 day moving average is $42.41 and its 200 day moving average is $33.55. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $55.72. The company has a market capitalization of $2.77 billion, a PE ratio of 259.73 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same period last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts expect that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on ATRC shares. Needham & Company LLC increased their price target on AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. UBS Group decreased their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Raymond James Financial set a $52.00 target price on AtriCure in a research report on Tuesday, July 21st. BTIG Research raised their target price on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. Finally, Piper Sandler boosted their price target on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

Institutional Investors Weigh In On AtriCure

Several large investors have recently added to or reduced their stakes in ATRC. Tidal Investments LLC lifted its stake in shares of AtriCure by 46.2% in the 2nd quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock valued at $534,000 after purchasing an additional 6,034 shares during the last quarter. WINTON GROUP Ltd purchased a new position in shares of AtriCure in the 2nd quarter worth approximately $1,002,000. Engineers Gate Manager LP increased its position in shares of AtriCure by 12.3% during the 2nd quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company’s stock valued at $1,348,000 after purchasing an additional 5,283 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in AtriCure during the 2nd quarter valued at $46,000. Finally, Allworth Financial LP raised its holdings in AtriCure by 372.8% during the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock valued at $43,000 after buying an additional 1,204 shares during the period. 99.11% of the stock is owned by institutional investors.

About AtriCure

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.